ONCODES.PREC.MED. EO-34
Research ONCODES.PREC.MED. EO-34 (ZR8) on Bullrun: market cap EUR 5.75M, P/E 1.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZR8
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 5.75M
- P/E1.0
- Financial periodFY2025
- RevenueEUR 261.15K
- Revenue growth26.1%
- Net incomeEUR 5.48M
- Gross margin3726.1%
Valuation Snapshot
latest market cap is EUR 5.75M; P/E is 1.0.
Peer valuation comparison
Latest P/E is 0.95x versus a Healthcare sector median of 24.46x (96.1% below).
Latest P/E is 0.95x versus a France median of 15.25x (93.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 261.15K | EUR 5.48M | n/a | 3726.1% | 0.3 | EUR 312.48K | EUR 6.36M | EUR 52.88M |
| FY2024 | EUR 207.04K | -EUR 7.21M | n/a | -3039.8% | -0.4 | EUR 436.92K | EUR 7.58M | -EUR 429.39K |
| FY2023 | EUR 1.07M | -EUR 8.09M | n/a | -615.4% | -0.49 | EUR 322.58K | EUR 8.83M | EUR 3.69M |
| FY2022 | EUR 7.98M | -EUR 231.18K | n/a | 5.8% | -0.01 | EUR 13.37M | EUR 2.60M | EUR 11.78M |
| FY2021 | EUR 3.83M | -EUR 2.94M | n/a | -51.6% | -0.43 | EUR 4.92M | EUR 2.91M | EUR 4.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 5.75M | 1.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ONCODES.PREC.MED. EO-34
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ONCODES.PREC.MED. EO-34's market cap?
ONCODES.PREC.MED. EO-34's market capitalization is EUR 5.75M.
What is ONCODES.PREC.MED. EO-34's P/E ratio?
ONCODES.PREC.MED. EO-34's price-to-earnings (P/E) ratio is 1.0.
What does ONCODES.PREC.MED. EO-34 do?
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers.